Claudin 18.2 and its role in advanced gastric cancers

Claudin 18.2 and its role in advanced gastric cancers
Claudin 18.2 (CLDN18.2) is a tight junction protein predominantly found in gastric epithelial cells. In gastric cancers, its expression becomes aberrant, making it a promising therapeutic target. Approximately 46.5% of resectable gastric cancer patients exhibit CLDN18.2 overexpression, which is associated with certain clinicopathological features but not independently linked to survival outcomes. This highlights the potential of CLDN18.2-targeted therapies, such as zolbetuximab, in treating advanced gastric cancers.

Share This Post

August 2022: The most apical portion of polarized epithelial and endothelial cells contains tight junctions, which are specialized membrane domains. The claudins, which are important proteins in tight junctions and have loops outside the cell, could be useful targets for diagnosis and treatment. They might be crucial in the development of tumors and inflammation.

In many types of epithelial cancers, changes in claudin levels have been shown to help tumors grow, influence cell signaling, and disrupt tight junctions. Malignancies damage tight junctions, leading to the loss of claudin proteins’ primary function. Many malignancies, such as gastric cancer (GC), hepatocellular carcinoma (HCC), biliary tract cancer (BTC), breast cancer, renal cell carcinoma, pancreatic cancer (PC), non-small cell lung cancer (NSCLC), and mesothelioma, have improperly regulated claudins.

 

Claudin 18.2 CAR T Cell therapy for Gastric Cancer Results

 

GC and PC are two malignancies that frequently express claudin 18.2, a member of the claudin family. Except for the gastric mucosa, healthy tissues do not express claudin 18.2. A new and powerful chimeric IgG1 monoclonal antibody called zolbetuximab, which attaches to claudin 18.2 on tumor cells, has recently been developed and is currently being tested in clinical trials. In a phase II trial (NCT01630083), patients with gastric cancer that have claudin 18.2 who received zolbetuximab along with standard chemotherapy lived longer on average than those who only received chemotherapy.

This encouraging finding shows that in order to expand the clinical applicability of this innovative drug to treat various cancer types, clinical trials utilizing it are required. The widespread expression of claudin 18.2 is a significant and remarkable finding for the treatment of cancer, given that patients who are positive for human epidermal growth factor receptor 2 (HER2) and who are currently being treated with the novel agent trastuzumab make up only 10–15% of all cases of GC (21).

The status of claudin 18.2 in various tumor types has not been thoroughly investigated using immunohistochemistry, which is significant (IHC). We conducted a study using claudin 18.2 IHC in a group of patients with various solid tumors to explore how claudin 18.2 can be used as a biomarker.

Susan Hau is a distinguished researcher in the field of cancer cell therapy, with a particular focus on T cell-based approaches and cancer vaccines. Her work spans several innovative treatment modalities, including CAR T-cell therapy, TIL (Tumor-Infiltrating Lymphocyte) therapy, and NK (Natural Killer) cell therapy.

Hau's expertise lies in cancer cell biology, where she has made significant contributions to understanding the complex interactions between immune cells and tumors.

Her research aims to enhance the efficacy of immunotherapies by manipulating the tumor microenvironment and exploring novel ways to activate and direct immune responses against cancer cells.

Throughout her career, Hau has collaborated with leading professors and researchers in the field of cancer treatment, both in the United States and China.

These international experiences have broadened her perspective and contributed to her innovative approach to cancer therapy development.

Hau's work is particularly focused on addressing the challenges of treating advanced and metastatic cancers. She has been involved in clinical trials evaluating the safety and efficacy of various immunotherapy approaches, including the promising Gamma Delta T cell therapy.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

PiggyBac Transposon System
AI & Technology

PiggyBac Transposon System: A Revolutionary Tool in Cancer Gene Therapy

The PiggyBac Transposon System is revolutionizing genetic engineering in cancer research, especially in CAR T-cell therapy. With its high integration efficiency and large cargo capacity, it provides a powerful, non-viral alternative to traditional gene delivery methods. Learn how PiggyBac is advancing personalized cancer treatment and shaping the future of oncology.

Breakthrough 2025 Treatments for Advanced Breast Cancer
Biotech Innovations

Breakthrough Treatments for Advanced Breast Cancer in 2025

In 2025, advanced breast cancer treatment has entered a new era. Precision medicine and targeted therapies are enabling doctors to tailor care based on genetic profiles. Immunotherapy and antibody-drug conjugates are delivering more effective tumor targeting, while experimental cellular treatments like CAR T-cell therapy show immense promise. These cutting-edge options are transforming outcomes and quality of life for patients facing metastatic breast cancer. Explore the latest innovations driving hope and progress.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

We Are Online! Chat With Us!
Scan the code